II. Indications

  1. All children as Primary Series at age 1 year
    1. Children are reservoir for Hepatitis A (May erradicate Hepatitis A from population)
  2. Travelers to endemic Hepatitis A areas
    1. All regions outside United States, Western Europe, New Zealand, Australia, Japan and Canada
  3. Close contact with international adoptee
  4. Children living in endemic states of United States
    1. Arizona (highest Prevalence in United States)
    2. Alaska
    3. Oregon
    4. New Mexico
    5. Utah
    6. Washington
    7. Oklahoma
    8. South Dakota
    9. Idaho
    10. Nevada
    11. California
  5. Food handlers
  6. Workers with primates
  7. Day care workers or children
  8. Illicit Drug use
  9. Homosexual male
  10. Chronic Liver Disease
  11. Clotting Factor disorder

III. Preparation

  1. See Twinrix
  2. Hepatitis A Vaccine (Havrix, Vaqta)

IV. Dosing: Havrix or Vaqta

  1. Start Vaccine at least 4 weeks before departure
    1. Give Hepatitis A Immunoglobulin if less than 4 weeks before departure
      1. See Hepatitis A Immunoglobulin for other indications
  2. Infants (>12 month)
    1. May also administer to ages 6-12 months for international travel to endemic regions
    2. Dose 1: 0.5 ml IM at month 0, after age 12 months (or after 6 months old, before travel to endemic region)
    3. Dose 2: 0.5 ml IM at month 6-12, at least 6 months after first dose
  3. Children (ages 1 to 18 years)
    1. Dose 1: 0.5 ml IM at month 0 (U.S. Primary Series administers at age 12 months)
    2. Dose 2: 0.5 ml IM at month 6-12 (U.S. Primary Series administers at age 18-24 months)
  4. Adult (ages 19 years and older)
    1. Dose 1: 1 ml IM at month 0
    2. Dose 2: 1 ml IM at month 6-12

V. Dosing: Indications for administering Immoglobulin in impending out of country travel

  1. Age under 1 year old (Immunoglobulin Alone)
  2. Serious comorbidity (Vaccine and Immunoglobulin)
  3. Age over 40 years old (Vaccine and immoglobulin)

VI. Precautions

  1. Safe in HIV
    1. See Immunization in HIV
  2. Safe in Pregnancy
    1. See Immunization in Pregnancy
  3. Not indicated for under age 1 years
    1. Use Hepatitis A Immunoglobulin for exposure

VII. Adverse Effects

  1. Purpura (ages 7 to 17 years old)

VIII. Efficacy

  1. Protective antibodies after dose 1
    1. Two weeks: 37% of patients
    2. Four weeks: >90% of patients
    3. Twenty-six weeks: 100% of patients
  2. Long-term protection occurs with dose 2
    1. Protection lasts at least 20 years after series
  3. Hepatitis A Incidence reduced 95% since Vaccine introduction

IX. Resources

  1. CDC Immunization Schedules (last accessed 10/28/2020)
    1. https://www.cdc.gov/vaccines/schedules/

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Hepatitis A Vaccines (C0170300)

Definition (MSH) Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022362
Swedish Hepatitit A-vacciner
Czech hepatitida A - vakcíny
Finnish Hepatiitti A -rokotteet
English Hepatitis A Vaccines, Hepatitis A Vaccines [Chemical/Ingredient], hepatitis a vaccines, vaccines hepatitis, hepatitis a vaccine, hepatitis vaccines, Hepatitis A Vaccine, Hepatovirus Vaccines, Vaccine, Hepatitis A, Vaccines, Hepatitis A, Vaccines, Hepatovirus, hepatitis A vaccine
Japanese A型肝炎ワクチン, ワクチン-肝炎ウイルス-A型, ワクチン-A型肝炎, 肝炎ワクチン-A型
Italian Vaccino contro l'epatite A, Vaccini contro l'epatite A
Polish Szczepionki przeciw zapaleniu wątroby A
French Vaccins anti-hépatite A, Vaccins antihépatite A
German Hepatitis A-Vakzine
Portuguese Vacinas contra Hepatite A
Spanish Vacunas contra la Hepatitis A

Ontology: Vaqta (C0379473)

Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022362
English VAQTA, Vaqta, Vaqta (obsolete)

Ontology: Havrix (C0700881)

Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022362
English havrix, Havrix, Havrix (obsolete)